Click Here to Register on Zoom Conference


CABS is one of the largest non-profit biopharmaceutical professional organizations in San Francisco Bay Area. We are very pleased to host our 22nd annual conference virtually on Oct 30, 2021. This year's conference theme is “Passion for Better Medicine - Leading Biotechnology and Innovation”. We are expecting to attract more than 600 attendees globally, from the life science and Biopharmaceutical industries. The conference features 2 keynote speeches, 19 podium presentations and 2 panel discussions. The covered topics include: cutting-edge science and technology including gene therapy, cell therapy and next generation cancer immunotherapy; patent and legal considerations in life sciences; latest developments in biopharmaceutical policies and regulations; cross-border investment trend and M&A deals in the life sciences field during the COVID-19 pandemic. 

Highlight of 2021 BioPacific Conference 

  • Targeted Cas9/gRNA delivery for potential in vivo genome editing
  • New technology to develop drugs for previously undruggable targets
  • Winners of the 2021 CABS K. Fong Award in Life Sciences
  • Machine learning for drug development
  • Cancer immunotherapy in the post checkpoint Inhibitor era
  • New technologies in cell therapy
  • A first-in-class small molecular drug developed for HIV treatment
  • Regulatory considerations for early cancer detection and precision oncology 
  • Status review of COVID-19 pandemic
  • Investment trend and deal discussions in biopharmaceutical industries
  • IP and patent highlights in recent years


Click Here to Register on Zoom Conference

Click Here to Know About Our Speakers and Panelists


Click Here to Know About Our Speakers and Panelists

Agenda.pdf

Abstracts (PDF)

Morning Session


8:30 AM – 8:50 AM

Breakout Room Networking

8:50 AM – 8:55 AM

Welcome Remarks

Carrie Wang, MD, President-Elect of CABS and 2021 BioPacific Conference Organizing Committee Chair

8:55 AM – 9:00 AM

State of the Society

Yang Tian, PhD, President of CABS

9:00 AM – 9:35 AM

Keynote 1: Traffic of Cas9-gRNA Between Cultured Human Cells Mediated by Cell-Cell Contact

Randy Schekman, PhD, Professor, Department of Molecular and Cell Biology, UC Berkeley

2013 Nobel Prize for Physiology or Medicine

9:35 AM – 10:00 AM

CABS K. Fong Award in Life Sciences

Fireside Chat, Presenter: Kenneth Fong, PhD, Chairman, Kenson Ventures LLC

Awardees: 

John O. Link, PhD, Former VP, Gilead Sciences, Inc (Retired)

Xian-Ping Lu, PhD, Founder, Chairman and CEO, ChipScreen BioSciences

10:00 AM-10:25 AM

K. Fong Award Speech: Reshaping Biotech Landscape in China

Xian-Ping Lu, PhD, Founder, Chairman and CEO, ChipScreen BioSciences Co.

10:25 AM – 10:50 AM

K. Fong Award Speech: Lenacapavir: A Twice-Yearly Dosed First-in-Class HIV Capsid Inhibitor 

John O. Link, PhD, Former VP, Gilead Sciences, Inc (Retired)

10:50 AM – 11:20 AM

Cancer Immunotherapy Trends and Highlights in the Post-Checkpoint Inhibitor Approval Era

Gary Starling, PhD, CSO, Xyphos Biosciences, Astellas Pharma Inc.

11:20 AM – 12:00 PM

Panel Discussion 1: IP Considerations and Investment Trends for Life Sciences

Session will cover intellectual property considerations for life science transactions, investment stories of new technologies, and discussions on a new company structure.

Moderator: Janet Xiao, JD, PhD, Partner, Head of China Life Sciences, Morrison & Foerster LLP 

Panelists:

Chuck Comey, Partner, Morrison & Foerster LLP

Sean Cao, MBA, PhD, Managing Director, CBC Group

Neil Desai, PhD, Founder & CEO, Aadi Bioscience, Inc

12:00 PM – 12:30 PM

Breakout Room Presentations 

Room 0: How to Choose Key Reagents for CAR-T Cell Therapy Development 

Teng Peng, PhD, Technique Application Manager, ACROBiosystems


Room 1: Effective Use of Science in the FDA Regulatory Process 

Bethany Hills, Partner, Morrison & Foerster LLP

Keunbong (KB) Do, JD, PhD, Associate, Morrison & Foerster LLP


Room 2. Precise and Efficient Non-viral CRISPR Gene Editing Solutions 

Lumeng Ye, PhD, Sr. Scientist, GenScript USA Inc.


Room 3: Humanized Models for Improved Preclinical Discovery and Assessment of Novel Immunotherapies

Jenna Frame, PhD, Manager, Scientific Communications & Marketing, Biocytogen Boston Corp.


Room 4: Atomic-resolution cryoEM and Its Impact on SBDD 

Larry Jin, PhD, COO, Wuxi Biortus Biosciences Co., Ltd.

What’s Ahead for the Biotech Industry: Another Wave or Low Tide? 

Michael Zhao, Co-founder, Q Bay (Boston) 


Room 5: Clinical Study in the US and China

Charles Li, MBA, MS, VP, Business Development, CR Medicon, a Pharmaron Company

Next-Generation DMSO-Free & Serum-Free Cryopreservation for Cell Therapy Manufacturing and Processing

Xiaoxi Wei, PhD, Co-founder & CEO, X-Therma Inc.

User Affiliate at Lawrence Berkeley National Laboratory


Room 6: Future of Targeted Therapies in Lung Cancer

Sanjeev Redkar, MBA, PhD, President and Co-Founder, Apollomics Inc.


Room 7.  Opportunities and Challenges in the Development of an Innovative Clinical Research Platform

Sophia Kan, Director of Marketing Strategy, GoBroad Healthcare Group

Alex J. Zhang, PhD, Chief Scientific Advisor, Hanhai International Inc.

Afternoon Session


12:30 PM – 1:05 PM

Keynote 2: Towards Universal Druggability 

Greg Verdine, PhD, Professor, Chemical Biology, Harvard University

1:05 PM – 1:35 PM

How We Use Stem Cells & Genomics for Guiding Precision Medicine

Joseph C. Wu, MD, PhD, Director of Stanford Cardiovascular Institute and the Simon H. Stertzer, MD, Professor of Medicine and Radiology, Stanford University

1:35 PM – 2:05 PM

Designing Better Molecules Faster and with Less Expense: Illustrations of the Transformative Impact of Physics-Based Modeling Combined with Machine Learning 

Matt Repasky, PhD, SVP, Life Sciences Products, Schrödinger Inc.

2:05 PM – 2:35 PM

The COVID-19 Pandemic: A Status Report

Arthur Reingold, MD, Professor and Head of the Division of Epidemiology at the School of Public Health, UC Berkeley

2:35 PM –3:15PM

Panel Discussion 2: Strategic Partnerships & Financing Trends for the Biotech Industry

Moderator: Cheni Kwok, CLP, PhD, Managing Partner & Founder, Linear Dreams LLC

Panelists: 

Edward Harrington, MBA, CFO, Genentech

Guo-Liang Yu, PhD, CEO, Apollomics Inc.

Dewan Zeng, MBA, PhD, Head of Search and Evaluation, Business Development, BeiGene, Ltd.

Cariad Chester, Partner, TCG Crossover “TCG X”

3:15 PM – 3:45 PM

FDA Experience and Regulatory Considerations on Companion Diagnostics and Cancer Early Detection Test

Sharon Liang, MD, RAC, PhD, VP, Regulatory Affairs and Quality Affairs, Burning Rock Dx, LLC

3:45 PM – 4:00 PM

A World-Class Healthcare Technology Innovation Platform at Hong Kong Science Park

Carrie Ling, PhD, Assistant Director of Business Development (InnoHK), Hong Kong Science and Technology Parks Corporation (HKSTP)

4:00 PM – 4:05 PM

Conference Adjourned

4:05 PM – 4:30 PM

Breakout Room Networking



Click Here to Register on Zoom Conference


Download 2021 BioPacific Conference Brochure



Thanks to our Sponsors!




Virtual Zoom Conference

Free Online Seminar: Radio-labeled Mass Balance and Metabolite Profiling Studies: Fundamentals, Best Practices, Regulatory Requirements, Applications, and Case Studies

Date/Time: Oct. 14 and Oct 15, 13:00-17:00 Eastern Time  

Venue: Online via Zoom by PBSS-Boston

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration:  https://www.pbss.org/aspx/homeBoston.aspx 



Zoom

EPPIC Global Presents:

Title - Healthcare Start-Ups: Opportunities, Challenges and Trends

When - 18 September 2021, 9:00-10:30am PDT
Registration -     Free for EPPIC Global Members
                            $20 for Non-Members

Link- https://eppicglobal.org/engage/calendar/#id=115&cid=1707&wid=1401&type=Cal



online
[Webinar] HKSTP Thought-leadership Series: AI for Cognitive Health
Sept 15, 2021 | 06:00 – 7:30 pm (PDT)
Online via Zoom
 
 
By 2030, 78 million people worldwide will be living with dementia and Alzheimar’s Diseases (AD) accounts for 60-70% of the cases, as per WHO’s forecast. Early diagnosis of AD is crucial for timely intervention to prolong lives and reduce healthcare costs.
 
Join the event and learn from CUHK and MIT researchers about the AI-driven research that automatically extracts spoken language biomarkers for early detection of AD.



Zoom

Oligo-Therapeutics Seminar

Organized by CABS Science & Technology Committee

Oligonucleotides have potential to revolutionize medicine due to their ability to target previously “undruggable” disease genes. The Chinese American Bio-Pharmaceutics Society (CABS) will host an Oligo-Therapeutics seminar on September 11th, 2021 at 1:00-4:30pm (PDT). Brought together Oligo experts from Ionis, Eli Lilly, and Amgen, the seminar will delve into the pioneering development of oligo-therapeutics from chemistry and delivery, biology/pharmacology, to clinical translation. Join us to get exposed to ground-breaking oligonucleotide science and case studies and to network with oligo industrial professionals.

Date: September 11th 2021, Saturday, 1:00-4:30 PM (PDT)

Zoom: https://zoom.us/webinar/register/WN_h_M02eYFSEKTWjN1WEwU7A

Agenda:

1:00 to 1:05 PM PDT Welcome Remarks from CABS. Xiang Yi, PhD, Co-chair, CABS Science & Technology

1:05 to 1:50 PM PDT Targeted Delivery of Oligonucleotide Therapeutics. Punit Seth, PhD, VP of Medicinal Chemistry, Ionis Pharmaceutics, San Diego

Abstract: Synthetic therapeutic oligonucleotides (STO) represent the third bonafide platform for drug discovery in the pharmaceutical industry after small molecule and protein therapeutics. No less than thirteen STOs have been approved by regulatory agencies and over one hundred of them are in different stages of clinical trials. STOs hybridize to their target RNA or DNA in cells via Watson-Crick base pairing and modulate their function to exert pharmacological effects. This unique class of therapeutic agents has the potential to target genes and gene products that are considered undruggable by other therapeutic platforms. However, STOs must overcome several extracellular and intracellular obstacles to interact with their biological RNA targets inside cells. These obstacles include degradation by extracellular nucleases, scavenging by the reticuloendothelial system, filtration by the kidney, traversing the capillary endothelium to access the tissue interstitium, cell-surface receptor-mediated endocytic uptake, and escape from endolysosomal compartments to access the nuclear and/or cytoplasmic compartments where their targets reside. Recent advances in the delivery of STOs will be presented.

1:50 to 2:35 PM PDT Discovery and Development of Oligonucleotide Therapeutics: Past, Present, and   Future. Gosia Gonciarz, PhD, SR. Director, Internal Platform Leader, New Therapeutic Modality, Eli Lilly and Company, Indianapolis

Abstract: Nucleic-acid based therapeutics are emerging new drug modalities beyond conventional small molecules, peptides and monoclonal antibodies, that offer new therapeutic avenues and solutions for unmet medical needs. Different classes of nucleic-acid therapies including antisense oligonucleotides, aptamers, small interfering RNAs, microRNAs, messenger RNA, viral vectors and CRISPR/Cas9 system are being evaluated in clinical trials or have already received regulatory approval. RNA-based therapeutics can act through different mechanisms ranging from activation to silencing and knockout of the target gene. The versatility of modes of action makes them popular therapeutic agents for various medical needs.

Unmodified RNA molecules are unstable, rapidly degraded and cleared from circulation. After years of dedicated research, major challenges associated with poor potency, stability and immune response activation have been overcome and led to discoveries of potent and durable RNA therapeutics. Antisense oligonucleotides (ASOs) and short interfering RNAs (siRNAs) are the most advanced and promising examples of this newer class of medicines. First wave of RNA therapies has been developed for treatment of rare indications such as spinal muscular atrophy, hereditary TTR-mediated amyloidosis and acute hepatic porphyria as exemplified by regulatory approvals of Spinraza, Onpattro and Givlaari respectively, building excitement and confidence in this new class of therapeutics. The next wave of RNA therapeutics might offer treatments for broader indications such as cardiovascular disease. Recent clinical readouts with inclisiran, an siRNA designed to inhibit the synthesis of the proprotein convertase subtilisin-kexin type 9 (PCSK9) to lower low-density lipoprotein cholesterol (LDL-C), suggest that RNA therapies could offer attractive therapeutic solutions to broad patient populations. As demonstrated in phase 3 clinical trial, a single subcutaneous injection of inclisiran can lower LDL-C level for 6 months. Long duration of action and infrequent administration of siRNA therapies is very attractive from various perspectives, including patient convenience, lower cost of goods and most importantly will significantly improve patient adherence to medication and as a result improve disease outcomes.

2:35 to 3:20 PM PDT siRNA Therapy in Metabolic Diseases. Jun Zhang, PhD, Principal Scientist, Amgen,   South San Francisco

Abstract: Since discovery in 1998, RNA interference (RNAi) become a widely used research tool to probe the importance of individual genes by knocking down gene expression. Ten years later, synthetic small interfering RNAs (siRNAs) were discovered with great potential as therapeutics to extend its targets beyond what can be achieved with small molecules and biologic. Recent progress in clinics further suggest that siRNA drugs are safe, effective with extremely long duration of action up to six months, presented revolutionary impact on pharmaceutical industry. These advantages are beneficial to chronic metabolic conditions such as T2D, NASH, cardiovascular disease (CVD), chronic lung conditions, which in general require therapeutics met high standards of safety, effectiveness, and easy administration. A summary of synthetic siRNA-based drug design and progress in therapeutic development will be discussed, with a focus on opportunities and challenges to overcome metabolism related disorders and syndromes. 

3:20 to 4:05 PM PDT Delivery of RNA Therapeutics: The Great Endosomal Escape! Steven Dowdy, PhD,      Professor, Dept. of Cellular & Molecular Medicine, UCSD, San Diego

Abstract: RNA therapeutics have great potential to selectively treat human disease, especially cancer, pandemics and CNS disorders. Due to their large 8-14 kiloDalton size and 20-40 or more negative phosphate charges, RNA therapeutics are too large to diffuse across the cell membrane and are instead taken up endocytosis.  However, >99% of RNA therapeutics remain trapped inside of endosomes with <1% escaping across the endosomal lipid bilayer membrane into the cytoplasm of cells. Consequently, endosomal escape remains The Technological Problem to solve for development and efficient delivery of all RNA therapeutics. Viruses also have an same endosomal escape problem, but have evolved mechanisms to solve it.  We developed new chemistry to synthesize a universal endosomal escape domain (uEED) that biomimics the mechanism that enveloped viruses use to escape the endosome. uEEDs can be conjugated to all RNA therapeutics.

4:05 to 4:30 PM PDT Panel discussion

Speakers Background:


Dr. Punit P. Seth heads medicinal chemistry and targeted delivery at Ionis Pharmaceuticals. Dr. Seth is co-inventor of Ionis’ Gen 2.5 platform which employs high affinity nucleoside modifications to enhance the affinity, stability and potency of ASOs in the liver and in extra-hepatic tissues. He is also the co-inventor of Ionis’ LICA (ligand conjugated antisense oligonucleotides) platform which enhances ASO potency by targeted delivery to cells and tissues of interest. He has extensive experience with using medicinal chemistry strategies to modulate the activity, pharmacokinetic and toxicological properties of oligonucleotide drugs. Dr. Seth is listed as co-author/co-inventor on over 200 peer-reviewed publications, issued patents and patent applications. He has a Ph.D. in organic chemistry from The Ohio State University.


Malgorzata (Gosia) Gonciarz is a Senior Director in Lilly’s Novel Therapeutic Modalities organization, where she leads a diverse group of scientists to design and develop RNA based therapeutics and enable their delivery to specific tissues.  Dr. Gonciarz received a M.S. in Biochemistry from the University of Wroclaw, Poland and a Ph.D. in Molecular and Cellular Biology from University of Gdansk, Poland. She then went on to post-doctoral work at University of Utah where she studied structure and function of cellular components. Dr. Gonciarz joined Lilly in 2009 and started her journey in Biotechnology Discovery Research organization where she has applied her expertise in protein engineering, structural biology, and biophysical characterization to advance peptide-, protein- and antibody-based therapeutics. Through her various scientific roles at Lilly, she led teams from early discovery through clinical proof-of-concepts advancing Lilly’s pipeline across breadth of therapeutic areas. 


Jun holds a Ph.D. in Molecular and Cellular Biology from Baylor College of Medicine and a Bachelor of Medicine from Peking University Health Science Center. Prior to joining industry, Jun was a Jane Coffin Childs Postdoctoral Fellow in Developmental Biology, Genetics and Bioengineering at HHMI and Stanford University School of Medicine from 2004 to 2009. She then worked at a startup Biotechnology company for over three years and joined Amgen in 2012. She has been leading multiple early discovery programs of innovative biologic, small molecule and nucleic acid therapies for treating metabolic diseases including diabetes, atherosclerosis, dyslipidemia and NASH.


Dr. Steven F. Dowdy is a Professor of Cellular & Molecular Medicine at UCSD School of Medicine and a cancer biologist, specializing in the development and delivery of RNA therapeutics, and G1 cell cycle control in cancer.  He received his Ph.D. in Molecular Genetics from UC Irvine with Prof. Eric Stanbridge working on tumor suppressor genes, and performed his postdoctoral fellowship with Prof. Bob Weinberg at the Whitehead Institute, MIT, working on the biochemistry of the Rb tumor suppressor gene.  His lab is focused on the molecular details of delivery of RNA therapeutics across the endosomal lipid bilayer and the synthesis of endosomal escape domains to overcome this billion year old rate-limiting barrier.  His lab was the first to synthesize bioreversible, charge neutralizing phosphotriester backbone RNAi prodrug triggers that increase metabolic stability, pharmacokinetics and enhance endosomal escape.  Dr. Dowdy sits on five biotech Science Advisory Boards and is an elected member of the Oligonucleotide Therapeutics Society (OTS) Board of Directors (2015-present). Previously, Dr. Dowdy was a Howard Hughes Medical Institute Investigator (1994-2012) and an Assistant Professor at Washington University School of Medicine, St. Louis (1994-2001).



Zoom

The Chinese American Biopharmaceutical Society (CABS) K. Fong Award Committee is very pleased to announce that Dr. John O. Link and Dr. Xian-Ping Lu are the winners of the 2021 CABS K. Fong Award in Life Sciences for their extraordinary achievements in research, entrepreneurship, and innovation. 


Dr. John O. Link

Dr. John O. Link has 30 years of experience in discovering and developing drugs as a medicinal chemist and project leader. John received his PhD in Chemistry under the direction of EJ Corey at Harvard University working on CBS reduction chemistry and a novel synthesis of amino-acids, now named the Corey-Link Reaction. John elucidated the inhibition mechanism of the immunosuppressant drug CellCept® along with the enzymatic mechanism of its target, inosine monophosphate dehydrogenase at Syntex/Roche Palo Alto. At Celera John worked in the inflammation and antiviral areas with three compounds entering clinical trials.  John was a Vice President of Medicinal Chemistry at Gilead Sciences and led the project teams that discovered the hepatitis C NS5A inhibitors ledipasvir and velpatasvir (Harvoni® Epclusa®) and continued as the project leader through Phase I clinical trials. The NS3/4a protease inhibitor drug voxilaprevir was discovered in his group (Vosevi®). John is co-inventor on the patents disclosing these three approved drugs. Under his leadership, Gilead moved three small molecule HCV inhibitors from discovery to FDA approval. Since their approval from 2014 to 2016, those HCV drugs have cured 1.5 million HCV patients globally by mid-2017. He is also a co-inventor and was a project leader on the first-in-class twice-yearly dosed Capsid inhibitor lenacapavir that is in multiple late-stage clinical trials for HIV treatment or prevention. John was awarded the American Chemical Society’s 2015 “Heroes of Chemistry Award” for his contributions to the discovery of Harvoni®, and in 2017 received the inaugural “Male Ally” award from the “Women at Gilead” employee resource group.


Dr. Xian-Ping Lu PhD

Dr. Xian-Ping Lu is Chairman, CEO of Shenzhen Chipscreen Biosciences Co. LTD. Dr. Lu founded Shenzhen Chipscreen Biosciences 20 years ago with a group of US-trained professionals. He built Chipscreen Biosciences into a leading Chinese drug discovery and development company focusing on innovative small molecular therapeutics. ChipScreen is probably the only truly innovative, vertically integrated biopharma company in China. Using active compounds as probes to characterize proteome functions, this novel approach allows small molecules to be systematically screened as new therapeutic targets, enhancing the ability to create target-specific chemical drugs. The chemical genomics approach led to the discovery of Chidamide, a highly selective histone deacetylase HDAC inhibitor. The approval of Chidamide also broke China’s reliance on foreign imports for innovative drugs. The out-licensing of its overseas patents brought Chipscreen large milestone payments and made Chidamide the first original Chinese drug authorized for use in the US and other countries. This sets a precedent for China to change from a drug imitator to a creator. 

Previously Dr. Lu was Director of Research at Galderma R&D in Princeton until 2000, the year he became visiting professor at China’s State Key Laboratory for Biomembrane and Membrane Biotechnology in Tsinghua University.  He also participated in founding Galderma Research Inc. and Maxia Pharmaceuticals in San Diego around 1994.

Dr. Lu came to the US in 1989 for postgraduate fellowship study at the Department of Pharmacology, University of California in San Diego, followed by research fellowship at La Jolla Cancer Research Foundation (Burnham Institute). He obtained his Ph.D. in Molecular Biology and M.S. in Biochemistry from Peking Union Medical College, Chinese Academy of Medical Sciences, and his B.S. degree in Biochemistry from Sichuan University. 

With over 30 years of biomedical research and biotech/pharmaceutical experience in various therapeutic areas, Dr. Lu is a skilled leader of diverse groups in global operating settings.  He has published more than 100 peer-reviewed papers in prestigious journals including Nature, Science and The Lancet.  He is the lead inventor on over 300 patented inventions in areas of small molecule therapeutics.

In the past 20 years, Dr. Lu has participated and promoted many reforms in regulatory environment, policy, and guideline of NMPA, reimbursement system of national health care, security and exchange of capital market, taxation and many others in China. He has been recognized as “China’s New Drug Trailblazer” as well as winning various prizes and recognitions from the pharmaceutical industry and other institutions. 

About CABS K. Fong Award in Life Sciences

CABS K. Fong Award in Life Sciences is presented annually to recognize those individuals who make significant contributions in life sciences and the biopharmaceutical industry including outstanding scientific findings, recognized efforts in promoting life science education and initiatives in improving life science community, and those who bring therapeutic breakthroughs to the market and improve healthcare and quality of life.

Candidates must be nominated by an active member of CABS. Selection criteria are based on candidate’s accomplishments in life sciences and contribution to the life science community, including one or all of the following:

  • Proven achievements in therapeutic breakthroughs (including discovery, process or clinical development), diagnostics or research reagent/equipment markets.
  • Significant contribution to the promotion of academic and industrial R&D in biomedical sciences and applications.
  • Significant contribution to the CABS community and promotion of international collaborations in life sciences.

About Dr. Kenneth Fong

Dr. Kenneth Fong has spent the last 32 years in the biotech industry after completing his academic pursuit in biomedical research.

He is best known for founding the biotech company, Clontech in 1984 which he built into one of the largest biomedical tool companies founded by an Asian American in the US (400 employees including 65 PhD scientists). Clontech was sold to Becton Dickinson in 1999 and Ken has continued his career as a Venture capitalist with Kenson Ventures that he founded. He has since cultivated more than 10 highly successful entrepreneurs, advising them and working with them on the growth of their companies.

Currently, he sits on the board of 4 biotech companies and he was intimately involved with the M/A and IPO of more than 10 companies that are worth more than $3 billion. These companies range from research tools, medical diagnostics and drug development. In almost all cases, Dr. Fong has been instrumental in providing strategies for sustainable growth, value creation and liquidity. Those successful entrepreneurs have moved on to assume leadership in other start-up and mid-sized companies, which in turn led to a new generation of entrepreneurs.

Ken has held a number of leadership positions over the years. He served as the President of the Society of Chinese Bioscientists in North America (2006-07) and President of the Bay Area Asian American Manufacturers' Association (AAMA, 1987). He was also a member of the Board of Trustees of the California State University System (2006-13). His philanthropic interests include scholarships to San Francisco State University, the Kenneth Fong-Hearst endowed scholarships to the CSU system and 40 student scholarships to Peking University. In 2006, he was involved with establishing the Fong Optometry and Medical library at UC Berkeley, and more recently an endowed professorship at Stanford University and a technology translation endowed fund at San Francisco State University.

Ken obtained his PhD from Indiana University and his BS from San Francisco State University.

Past recipients of CABS K. Fong Awards

2019: Dr. John V. Oyler, Chairman, Co-Found and CEO of BeiGene, for his entrepreneurship and business leadership to establish BeiGene as a world-class biopharmaceutical company.

2018: Dr. Yuling Luo, Founder, CEO and Chairman of Alamar Biosciences, and Dr. Guoliang Yu, Executive Chairman of Crown Bioscience, for their successful serial entrepreneurship in the life science business.  

2017: Dr. Yinxiang Wang, Co-founder and CSO of Beta Pharma, for his role in leading development and commercialization of Conmana®, the first small molecule oncology drug specifically targeting cancer cells that was completely developed in China, and Dr. Edgar Engleman, for his pioneering research that was the basis of the Sipuleucel-T (Provenge) prostate cancer vaccine, the first active immunotherapy for cancer to be approved by the FDA.

2016: Dr. Gerald Chan, co-founder of Morningside, for his extraordinary vision and leadership in cultivating a generation of successful entrepreneurs and life sciences companies.

2015: Dr. Irving Weissman, of Stanford University, for his pioneering work in stem cell research.

2014: Dr. Ge Li, Founder and CEO of Wuxi Apptec, for creating and shaping the CRO business model in China and Dr. Hing L. Sham, formerly of Abbott for his leading role in the discovery of life- saving HIV protease inhibitors, ritonavir and Iopinavir.

2013: Dr. Peter Hirth, Plexxikon & Sugen for his pivotal role in advancing 4 successful drugs to the market and Dr. Jean Cui, formerly of Pfizer for her role as the lead designer and investigator of crizotinib, a successful kinase inhibiting drug used in personalized medicine.
online
HKSTP Thought-leadership Series: Combating Emerging Infectious Diseases

17 Aug, 2021 | 05:30pm (PDT)

Online via Zoom | English

Join us and learn comprehensive knowledge from a group of top-notch researchers across the world how to effectively address emerging infectious diseases threats

Register Now: https://bit.ly/3xxKW0m



Zoom

Free Online Symposium: Advances in Immuno-Oncology

Date/Time: Aug 11 & 12, 2021; 8:30 - 13:00 (Pacific) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration: https://www.pbss.org/aspx/homeSF.aspx



Zoom

To serve our community, the Chinese American Bio/Pharmaceutical Society (CABS) is delighted to host a FREE Virtual Job Fair on Zoom on August 7, 2021 from 2PM to 5PM Pacific time (5PM-8PM Eastern time). We have more than twenty entities that will participate in this event and intend to recruit talents for 80+ positions in US, Mainland China, and Hong Kong (as of July 15, 2021). See the flyer and registration link for job posting details. (Note that the job postings are continuously being updated on our website.) During the Job Fair, each participating entity will have an individual break room, where you will have opportunity to directly speak with the hiring team to explore career opportunities. There will also be a show room where featured entities will showcase their visions and talent recruiting objectives.

 

To register, please click Meeting Registration - Zoomor scan the barcode on the flyer.      

 

For entities that are interested in participating this event, we still have limited FREE spots available. You will have the privilege of 1) promoting job postings via CABS website prior to the event for free, and 2) an individual breakroom for your hiring team to directly interact with potential candidates on the day of the Job Fair. First come, first serve! Please contact cabs_bcd@cabsweb.org ASAP if interested.



Zoom

CBA SF is inviting you to a scheduled Zoom meeting.

Topic: Diet, Microbiota and Cancer by Dr. Pan

Time: Jul 31, 2021 10:00 AM Pacific Time (US and Canada)



Zoom

Free Online Symposium: Development of Inhalation Therapeutics

Date/Time: July 29 & 30, 2021; 8:30 - 12:30 (Pacific) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration: https://www.pbss.org/aspx/homeSF.aspx



Zoom

CBA SF is inviting you to a scheduled Zoom meeting.

Topic: Checkpoint Inhibitors' Immune-Mediated Side Effects, A Perspective from A Non-Oncologist Physician.

Time: Jul 17, 2021 10:00 AM Pacific Time (US and Canada)

Join Zoom Meeting

https://zoom.us/j/94036197939?pwd=bm5sOFpGblRLelp2bVpIUDlyL3JxQT09

Meeting ID: 940 3619 7939

Passcode: 2021



Zoom

Free Online Seminar: Statins for Cholesterol Control: Historical Stories and Lessons Learned

Date/Time: July 15, 2021; 11:30 - 13:00 (Pacific) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration: https://www.pbss.org/aspx/homeSF.aspx



Zoom
Title - Progress and Challenge of Gene Editing Technologies
Time - Sat, 26 June 2021 from 2-3:30 PDT
Where: https://lnkd.in/gG4rvgD (Click the link to register)
               Free for EPPIC Global Members
              $20 for Non-members

Gene editing based therapeutics have tremendous clinical potential and are currently being investigated for a variety of indications.  However, several challenges need to be solved before the clinical potential of gene editing can be realized. In this presentation, Professor Niren Murthy (UC Berkeley) and Dr. Kunwoo Lee (CEO of GenEdit) will discuss the history of gene editing and present an overview of exciting recent developments in the field. Clinical stage ex vivo approaches targeting disorders like sickle cell disease, cancer, and HIV, and in vivo approaches targeting monogenic disorders in various tissues will be discussed. In addition, they will present recent work of their own, which is focused on solving the delivery challenges associated with in vivo gene editing. Following the presentation, Dr. Derek Sloan from GenEdit will moderate an audience Q&A session.



online

Have you always wanted to improve public speaking skills but don't know where to start?

Would you want to get a taste for public speaking in a relaxed, outdoor setting?

Or maybe you are just tired of Zoom meetings all the time and want to see some friendly faces in person?

You are invited to the open house hosted by the BioPacific Toastmasters Club on Sat, Jun 19th, 2021, 9:45-11:15 AM PDT at Ryder Park in San Mateo.

You will hear wonderful speeches while enjoying the blue sky and fresh air. Please find more details and register at: 

https://forms.gle/imjE2M67x4KHgsYH8




Ryder Park: 1801 J Hart Clinton Dr, San Mateo, CA 94401

Free Online Symposium: Antibody-Drug Conjugates: Discovery to Development

Date/Time: May 26, 2021; 8:30 - 13:30 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration: https://www.pbss.org/aspx/homeSF.aspx



Online via Zoom by PBSS-SF Bay

ChinaBio® Partnering Forum 2021

Shanghai and Digital

May 10-14, 2021

www.CBPF2021.com

ChinaBio® Partnering Forum has grown to be the premier life science partnering conference in China since 2009. ChinaBio® Partnering Forum 2021, in its new hybrid delivery, will kick off with two days of productive in-person one-to-one meetings in Shanghai, China followed by three days of effortless virtual one-to-one meetings. That enables you to identify, meet and network with leaders across the life science value chain to accelerate your cross-border partnerships and expand your reach into the China market. ChinaBio® Partnering Forum 2020 was a busy three days, August 2527, 2020, with 1,000 delegates representing 34 countries engaged in over 3,200 virtual partnering meetings. Additionally, delegates engaged with 8 program sessions, over 60 company presentations and over 20 Company Showcases, all available on demand and accessible from anywhere in the world. 


ChinaBio® 合作论坛2021

上海和数字版

2021510-14

www.CBPF2021.com

 

ChinaBio®合作论坛是中国首屈一指的生命科学合作会议。今年第十三届ChinaBio合作论坛组合版,将以崭新的线下和线上双重模式举行,会议前两天与会者在上海进行现场一对一合作会议、圆桌讨论和欢迎酒会等内容,世界各地的与会者则在会议后三天继续参与数字化的远程合作会议。这将帮助您找到生命科学行业价值链中的领先者,与他们会面并建立联系,从而加速您的跨境合作伙伴关系并进一步延伸您在中国市场的触角。去年首次数字版会议,凭借全球最大的生命科学合作活动提供商EBD Group提供的强大在线平台,来自34个国家/地区的1000多名与会者在为期3天的会议中进行了3200多次一对一会议、60个公司路演和20个公司展览展示。

 

CABS会员凭推广代码CABS20,享受20%的注册优惠。

 





Shanghai and Digital

Due to COVID-19 situation, CABS Board of Directors have decided to postpone CABS 2020 BioPacific Conference to October 30th, 2021 (Saturday). The conference venue will be the same: San Mateo Marriott Hotel. The election of 2020 CABS President-elect, Executive Council (EC) and transition of CABS presidency will also be postponed from September, 2020 to October, 2021. Current CABS President, President-elect and EC team will stay on duty until October, 2021. 

CABS community's health and safety is our No.1 priority. We are one of the first professional organizations national-wide to cancel large social gathering events in anticipating the potential outbreak of Coronavirus infection back to January of this year. Postponing 2020 BioPacific Conference is a continuation of our policy to safeguard our community.

Current CABS EC team has been working together as a unified force to combat COVID-19 and serve our community. The team's willingness to serve for one more year is a testament of our strength and commitment to you during this crisis. CABS will continue leading our community efforts to combat COVID-19 and to provide more online forums to share the latest development in COVID-19 diagnostics and treatment and also in other areas of drug discovery. 

For sponsors and exhibitors who have already committed to 2020 CABS BioPacific Conference, your reserved sponsorship/exhibitor spots will be carried over to 2021 conference. As an appreciation of your support at this critical moment, we will continue promoting your company brand names to our community from now until the end of 2021. There are still spots left for sponsor/exhibitors of 2021 BioPacific Conference. If interested, please contact fundraising@cabsweb.org for details. 

A big thank-you to speakers/panelists who have already accepted our invitation to present at 2020 BioPacific Conference. We hope you are available for 2021 Conference on May 8th, 2021. CABS volunteers will reach out to you for details. 

Finally, we sincerely thank 2019-2020 term CABS EC members and volunteers,  for your team efforts in combating COVID-19 and your commitment to serve CABS for two years. Your efforts and diligent work will be special and important to our community. 

Sincerely and Best

CABS Board of Directors and President

04/06/2020



Announcement

Scientific Seminar: Ongoing Battle Against Covid-19: Therapeutic Antibody Development

Time: April 24, Saturday, 4:30-7:00 PM Pacific Time; 7:30-10:00 PM Eastern Time; April 25, Sunday, 7:30 – 10:00 AM China Time)

Length: 2.5 hours

Format: Short Presentations and Panel Discussion

Webinar Platform: Zoom Conference (be able to host up to 1,000 attendees simultaneously)

Registration Link: https://bit.ly/3wCYpVv


Speakers Bios:

Henry Ji, Ph.D. 

Chairman, President and CEO


25+ years of experience in the biotechnology and life sciences industry

Dr. Ji co-founded Sorrento and has served as a director since 2006, CEO and President since 2012, and Chairman since 2017

During his tenure at Sorrento, he has engineered and led a phenomenal growth of Sorrento through acquisition and merger including Bioserv, ScilexPharmaceuticals, Concortis Biotherapeutics, LevenaBiopharma, LACEL, TNK Therapeutics, Virttu Biologics, Ark Animal Health, and Sofusa Lymphatic Delivery Systems

Served as Sorrento’s Chief Scientific Officer from 2008 to 2012 and as its Interim CEO from 2011 to 2012

Prior to Sorrento, he held senior executive positions at CombiMatrix, Strategen and also co-founded Stratagene Genomics, a subsidiary of Stratagene, and served as its President & CEO and Director of the Board

B.S. and Ph.D.

Yang Liu, PhD 


Chairman, Chief Executive Officer and Chief Scientific Officer, OncoC4, Inc. Rockville, Maryland

Chairman, AcroImmune, Guangzhou, China

Dr. Liu is currently the Chairman, CEO and CSO of OncoC4 and was the Director and Professor of the Institute of Human Virology and Department of Surgery at the University of Maryland at Baltimore. Dr. Liu has received many distinguished awards including the AAAS fellow. Dr. Liu’s  laboratory established Sialoside-based pattern recognition as a mechanism of self-nonself discrimination in innate immunity. Recently, Dr. Liu co-founded and led OncoImmune, Inc to translate this original discovery into a drug for treatment of multiple human diseases. OncoImmunerecently obtained clinical proof-of-concept data in a multi-center, randomized double blind clinical phase III trial showing that our first-in-class new drug significantly accelerated clinical recovery and reduced disease progress of patients with severe and critical COVID-19.

Liang Schweizer, PhD


Chief Executive Officer and Chief Scientific Officer

Liang Schweizeris the Co-founder, President and CEO of HiFiBiOTherapeutics. Previously, she co-founded HarbourBiomed and served as its CSO, successfully transforming a technology platform company to an antibody drug discovery enterprise.

Before launching her entrepreneurial career, Liang served as Head of Asian Cancer Research at Sanofi, advancing Sanofi’s Asia-Pacific oncology pipeline as well as contributing to global oncology programs from preclinical to clinical efforts. Before joining Sanofi, Liang Schweizerwas a director at Bristol-Myers Squibb Company, heading a group of scientists at Leads Discovery and Optimization (LDO), overseeing 60+ in vitro pharmacology projects across different therapeutic areas. Under her leadership, the team made significant contributions to 4 marketed drugs and impacted over 20 clinical candidates. She is also a co-inventor of multiple BMS Immunoncology(IO) clinical candidates.

Liang Schweizergraduated from the University of Science and Technology of China (USTC) majoring in Biology. She received her Master’s degree in Microbial Engineering at the University of Minnesota with minor in Chemical Engineering. Liang earned her Ph.D. in Molecular Biology from the University in Zurich, Switzerland. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC), New York.

Bolyn Hubby, PhD


Chief Corporate Affairs Officer

VirBiotechnology, Inc.

Bolyn Hubby, Ph.D., has served as our Chief Corporate Affairs Officer since August 2020. In this role, she is leading our Public Private Partnerships (P3), Government Affairs, Corporate Communications, Patient Advocacy efforts, and is a member of Vir’s Research Leadership Team. Prior to this role, she served as our Senior Vice President of Research and P3 since June 2019 and served in other management roles at Vir since February 2018. From January 2017 to January 2018, Dr. Hubby was the Chief Scientific Officer at AgenovirCorporation, a gene editing company we acquired in May 2018. Prior to Agenovir, Dr. Hubby worked for Synthetic Genomics Inc. from 2013-2017, where she most recently served as Vice President of Vaccines and Antimicrobials. At Synthetic Genomics, Dr. Hubby and her colleagues advanced the company’s core synthetic biology technology for influenza vaccines into the clinic and developed novel RNA and antimicrobial platforms to address the rapid spread of infectious disease and the growing global threat of antibiotic resistance. Prior to Synthetic Genomics, Dr. Hubby served as Executive Director of Vaccines at LiquidiaTechnologies, Inc. and Head of Discovery Immunology at AlphaVax, Inc. Dr. Hubby received her B.A. in Anthropology from University of Georgia and her Ph.D. in Cell Biology from the University of Georgia, Department of Cellular Biology and Center for Tropical and Emerging Diseases.

Moderator

Dr. Michelle M Chen

 

Dr. Michelle Chen is Vice President and Head of Corporate Development at WuXi Biologics where she leads corporate strategies, M&A, licensing, strategic partnerships, joint ventures, newcoformation and other initiatives.  As a biotech executive and entrepreneur, she has over 20 years of industry experience in drug discovery and development, diagnostics, and technology/product development, with a track record of success in partnerships, R&D, product development and launches.  Prior to WuXiBiologics, she worked at global companies such as BioMarin, Merck, and Roche, as well as a number of biotech companies and startups in various functions.

Dr. Chen received her Ph.D. in Biochemistry from the University of Washington, did her postdoctoral work at UCSF, and received bioinformatics training at Stanford University.  She is a board member of BayHelix and a life member of BayHelix, CABS and CAB.



Free Virtual Symposium

Stanford Drug Discovery Symposium 2021

Free Virtual Symposium

April 19 – April 20, 2021

The meeting has very high level speakers that include CEOs, CSOs, and Senior Vice Presidents from many pharmaceutical companies, government officials, and venture capital groups. This year’s virtual meeting will be open to all with no registration fee.

Details and registration: tinyurl.com/sdds2021




Free Virtual Symposium

Free Online Symposium: Challenges and Successes in Newly Approved Therapeutics

Date/Time: Apr 16, 2021; 8:30 - 12:30 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration: https://www.pbss.org/aspx/homeSF.aspx



Online via Zoom by PBSS-SF Bay

Title - The Story of Pfizer-BioNTech COVID-19 Vaccine". 

Time - Sat, 3/27, 2:00-3:30PM PST

Wherehttps://lnkd.in/gwPq5_E (Click the link to register)

Would you like to hear a first-person account from the Director of Viral Vaccines at Pfizer, Dr. Kena Swanson, who works in Vaccine Research and Development and was closely involved in the discovery and development of Pfizer, one of the first vaccines approved by FDA in Dec'20 for treatment of CoV-2 infection? Come join us on 27th Mar'21 from 2:00PM-3:30PM PDT for a Q&A moderated by Dr. Colby Shemesh and Dr. Denison Kuruvilla!





online

您是否有过关于薪酬,晋升,或者职业规划方面的困惑? CABS非常荣幸得邀请到对北美生命科学行业人才培养和事业指导方面拥有丰富经验的Kay Tong女士 和Jonathan Wong先生于3月26日(周五)下午四点(美西时间)/七点(美东时间)做一个百分百真诚的线上分享 (具体信息见海报)。Kay和Jonathan希望此次活动能尽可能多的和参会者交流,因此这次活动将限于50名参会者。活动免费,无需注册,欢迎大家参加。Zoom link:https://zoom.us/j/99391671885或扫描海报二维码。

(注:当参会者到达50人后,会议将被锁住,不再开放。所以请准时加入会议)。

另:如有问题希望Kay和Jonathan在panel中解答,请在3月19日之前email给youyuy@gmail.com

Do you ever have questions about compensation/promotion/career strategies? Come to this CABS Happy Hour Zoom event on March 26 (Friday) 4PM Pacific (i.e., 7PM Eastern) to get an honest perspective of two insightful speakers, Kay Tong and Jonathan Wong. Kay and Jonathan have extensive experiences in career coaching and talent acquisition for entry and mid-level professionals in life sciences industry in the US. (See flyer for more information.)

This is a free event. No registration is required. As Kay and Jonathan prefer to have open discussion with attendees as much as possible, this zoom event will be limited to 50 attendees. Zoom link: https://zoom.us/j/99391671885.

[Note: the meeting will be locked after the number of attendees reach 50. Therefore, please join the meeting on time.]

If you have any questions that you hope Kay or Jonathan to address, please send the questions to youyuy@gmail.comby March 19.





Online Zoom conference (register on Zoom below)

Free Online Symposium: Cardiac Safety from Preclinical to the Clinic: Industry and Regulatory Trends in T-QT and Concentration-QT Studies for Assessing QT Prolongation Risks 

Date/Time: Mar 23 & 24, 2021; 8:30 - 12:30 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration: https://www.pbss.org/aspx/homeSF.aspx




Online via Zoom by PBSS-SF Bay

Free Online Symposium: COVID-19 Pandemic - Rapid Pivoting from Oncological to Antiviral Small Drug Development

Date/Time: Mar 19, 2021; 10:30 - 11:30 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration: https://www.pbss.org/aspx/homeSF.aspx




Online via Zoom by PBSS-SF Bay

Free Online Workshop: Metabolite Identification: Strategies, Techniques and Case Studies 

Date/Time: Mar 9 & 10, 2021; 8:30 - 12:30 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration: https://www.pbss.org/aspx/homeSF.aspx




Online via Zoom by PBSS-SF Bay

COVID-19 Small Molecule Drug Discovery Webinar

Organized by CABS Science & Technology Committee

COVID-19, caused by SARS-CoV-2, is a global health and economic catastrophe. The main protease (Mpro) and the papain-like protease (PLPro) are essential for SARS-CoV-2 replication and thus are the compelling targets for small molecule anti-COVID-19 drug discovery. Regulating proteases in other viruses has been proven to be a successful pathway in the treatment of virus-caused diseases such as HIV and HCV. With progress on the understanding of these protein structures by collecting their high quality X-ray data, drug design and medicinal chemistry are being accelerated by computational tools to efficiently identify potent small molecule inhibitors. It’s of great hope that some breakthrough discovery may be achievable in a short period of time through integrated efforts and collaborations. We are happy to bring these scientists and specialists together to present you a CABS online webinar about COVID-19 small molecule drug discovery. You will hear their recent discovery and thoughts about how we should conquer this virus. You are welcome to join and we are looking forward to your participation and scientific discussion. 

Date: February 27th 2021, Saturday, 1:30-5:30 PM (Pacific Time).

Zoom: https://zoom.us/j/97482889026

Agenda:

1:30 to 1:35 PM Welcome Remarks from CABS. Ken Zhang, PhD, Co-Chair, STC, CABS.

1:35 to 2:15 PM Drug Repurposing for Treatment of COVID-19 and Inflammation-related Diseases Guided by Novel Computational Algorithms. Chang-Guo Zhan, PhD, Endowed Professor of Pharmaceutical Sciences and Director of Molecular Modeling and Biopharmaceutical Center, College of Pharmacy, University of Kentucky.

Abstract: In this talk, I will briefly talk about the applications of our recently developed novel computational algorithms to small-molecule drug repurposing for treatment of COVID-19 and inflammation-related diseases. Particularly for COVID-19, we have identified drugs suitable for the antiviral treatment targeting SARS-CoV-2 main protease and anti-inflammatory treatment of the COVID-19 hyperinflammatory (or cytokine storm).

2:15 to 2:55 PM How to Stop the Heart of a Virus: Specific Inhibitors and Clinical Drug Repurposing to Target SARS-CoV-2 Main Protease using X-rays, Neutrons and Computation. Andrey Kovalevsky, PhD, Senior R&D Scientist, Neutron Scattering Division, Oak Ridge National Laboratory.

Abstract: Computer-assisted and structure-guided drug design strategies rely on atomic scale understanding of the target biomacromolecule traditionally derived from X-ray crystallographic data collected at cryogenic temperatures. Conventional protein X-ray crystallography studies are limited by cryo-artifacts and its inability to locate the functional hydrogen atoms crucial for understanding chemistry occurring in enzyme active sites. Neutrons are an ideal probe to observe the protonation states of ionizable amino acids at near-physiological temperature, such as the non-canonical Cys-His catalytic dyad of SARS-CoV-2 Mpro. Our X-ray crystal structures of Mpro collected at near-physiological temperatures brought rapid insights into the reactivity of the catalytic cysteine, malleability of the active site, and binding modes with clinical protease inhibitors. The neutron crystal structures of ligand-free and ligand-bound Mpro were determined allowing the direct observation of protonation states of a catalytic site in a cysteine protease for the first time. At rest, the catalytic Cys-His dyad exists in the reactive zwitterionic state, with charged thiolate and doubly protonated imidazole side chains, instead of the anticipated neutral state. Ligand binding results in modulation of the protonation states, retaining the overall electric charge of the active site cavity. Our research is providing real-time data for atomistic design and discovery of Mpro inhibitors to combat the COVID-19 pandemic and prepare for future threats from pathogenic coronaviruses.

2:55 to 3:35 PM Targeting the SARS-CoV-2 Main Protease for Drug Discovery. Wenshe Ray Liu, PhD, Gradipore Chair and Professor in Chemistry, Texas A&M University.

Abstract: By targeting the essential main protease of SARS-CoV-2, the COVID-19 pathogen, a series of small molecule antivirals have been developed and tested on their inhibition of SARS-CoV-2 infection of human cells. Potent inhibitors include bepridil, a FDA approved medicine and a number of aldehyde-based compounds that form a covalent bond with the catalytic cysteine in the enzyme active site.

3:35 to 3:40 PM Break.

3:40 to 4:20 PM Drug Discovery Targeting SARS-CoV-2 Main Protease and Papain-like Protease. Jun Wang, PhD, Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona.

Abstract: SARS-CoV-2 encodes two viral proteases, the main protease (Mpro) and the papain-like protease (PLPro). These two proteases cleave the viral polyproteins during the viral replication and are validated antiviral drug targets. In addition, PLpro has been shown to suppress host immune response. In this presentation, I will introduce our efforts in developing inhibitors targeting Mpro and PLpro. Through high-throughput screening and subsequent structure-based drug design, several inhibitors have been identified with both potent enzymatic inhibition and cellular antiviral activity against SARS-CoV-2. To elucidate their mechanism of action, we solved multiple X-ray co-crystal structures of Mpro and PLpro with inhibitors. The significance of our study is the discovery of dual inhibitors targeting both viral Mpro and host cathepsin L, both of which are critical for the viral replication.

4:20 to 5:00 PM Remdesivir’s Inhibition of SARS-CoV-2 RNA Polymerization. Jason Perry, PhD, Senior Director, Structural Chemistry Department, Gilead Sciences.

Abstract: (TBD).

5:00 to 5:30 PM Panel Discussion. Host and All Speakers.

Speakers Background:


Dr. Chang-Guo Zhan is an Endowed Professor of Pharmaceutical Sciences and Director of Molecular Modeling and Biopharmaceutical Center in the College of Pharmacy, University of Kentucky. He also serves as Director of Chemoinformatics and Drug Design Core of the Center for Pharmaceutical Research and Innovation (CPRI) at the University of Kentucky.

With a research activity ranging from basic sciences to practical clinical applications, Dr. Zhan has published more than 390 scientific papers in peer-reviewed journals and has 55 patents or patent applications. Dr. Zhan’s current research interests are mainly focused on rational design, discovery, and development of novel therapeutics, as well as drug repurposing. Two of designed novel therapeutic candidates designed by him have completed Phase II clinical trials in humans; one received the Breakthrough Therapy designation by the FDA and is currently in preparation of Phase III clinical trial. Another long-acting protein drug candidate is heading to Phase I clinical trial. He has been very successful in securing nationally competitive research funding from the NIH, NSF, DoD, and other funding resourcesincluding more than $33M as PI since 2003.

At the University of Kentucky, Dr. Zhan was named as University Research Professor by the President and Board of Trusty in 2016, and won Kirwan Prize (the highest research award at the University of Kentucky) in 2017. He was a winner of 2005 Emerging Computational Technology Prize, American Chemical Society (ACS) Division of Computers in Chemistry, and is the current recipient of the NIDA Translational Avant-Garde Award from the NIH. Dr. Zhan was elected AAPS Fellow in 2010, and won 2016 AAPS Research Achievement Award in Drug Discovery and Development Interface.


Dr. Andrey Kovalevsky is a structural biologist, biochemist and neutron instrument scientist at Oak Ridge National Laboratory (ORNL). His current research focuses on the atomic level understanding of protein function, structure-guided drug design and drug resistance utilizing biophysical methods in combination with molecular simulations. Kovalevsky studied organic chemistry and crystallography at Kharkov State University, Kharkov, Ukraine, receiving his M.Sc. degree with Honors, and worked as a Research Assistant at Nesmeyanov Institute of Organoelement Compounds, Moscow, Russia. He received his Ph.D. in Physical Chemistry from University at Buffalo, The State University of New York. He studied macromolecular crystallography, biochemistry and molecular biology while working as a Postdoctoral Associate at Georgia State University. He held a Director’s Postdoctoral Fellowship and a Staff Scientist position while at Los Alamos National Laboratory. Currently, Dr. Kovalevsky is a Senior R&D scientist at the Neutron Scattering Division (ORNL).


Dr. Wenshe Ray Liu received his BS degree from Peking University in 2000 and PhD degree from UCDavis in 2005. He did two year postdoc in Scripps and started his independent research career at Texas A&M University in 2007 as an assistant professor. He was promoted to Associate Professor in 2013 and then Full Professor in 2016. Dr. Liu is the current holder of Gradipore Chair in Chemistry at Texas A&M University. Dr. Liu was a previous director of the TAMU Chemistry Mass Spectrometry Laboratory. He is currently chairing the Chemical Biology division in the Chemistry Department and the director of the Texas A&M Drug Discovery Laboratory. He is leading a chemical biology and drug discovery research group. 


Dr. Jun Wang received the B.Sc in chemistry from Wuhan University in 2003, the M.Sc in chemistry from National University in Singapore in 2006, and Ph.D. in chemistry from University of Pennsylvania in 2010. He was a postdoc first at the University of Pennsylvania, then at UCSF.  He started his independent career as an assistant professor at the University of Arizona, College of Pharmacy in 2014. He was promoted to associate professor with tenure in 2020. The Wang Laboratory focuses on developing antivirals targeting drug-resistant viruses and emerging viruses, including influenza A and B viruses, enterovirus D68 (EV-D68), EV-A71, coxsackievirus, poliovirus, and the recently emerged SARS-CoV-2. 


Dr. Jason Perry is a Senior Director in the Structural Chemistry Department at Gilead Sciences.  As a member of the modeling group for nearly 15 years, he has contributed to over two dozen research programs.  His primary focus has been in the area of Antivirals, where he has helped in the discovery and characterization of five approved drugs.  Prior to joining Gilead, he was an Applications Scientist at Schrodinger for 11 years, where he worked with researchers all over the US in getting the most out of their modeling software.  He received his BA from Johns Hopkins and his PhD from Caltech, where he worked in the labs of Bill Goddard.



Online Zoom conference

Event Title: The “China Initiative” and Your Research Grants

Date: Thursday, February 25, 2021

Registration link: https://communications.dorsey.com/230/2356/landing-pages/rsvp--prefill.asp?sid=blankform

Zoom link will be provided after registration

Agenda and detailed event info (include any web links as applicable):

SCHEDULE & DETAILS

8:00 p.m. – 9:30 p.m. EST

5:00 p.m. – 6:30 p.m. PST

9:00 a.m. – 10:30 a.m. Beijing Time

 

Web links: https://communications.dorsey.com/230/2356/compose-email/you-re-invited--the--china-initiative--and-your-research-grants-(2-25)-forward-friendly.asp 



online webinar

Biopacific Toastmaster is going to hold the evaluation contest and open house in one single meeting on Feb 20th 2021. Please join us for a session to learn from the evaluation contestants and to socialize!
Registration can be done through scanning the barcode in the flyer. Zoom link will be sent after registration is confirmed.


Online Zoom conference (register on Zoom below)

Free Online Symposium: Oxbryta® (Voxelotor) Tablets For Sickle cell Disease: The R&D Journey and Lessons Learned (a joint symposium by PBSS and CLSA)

Date/Time: Feb 16, 2021; 12:00 - 13:30 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration: https://www.pbss.org/aspx/homeSF.aspx





Online via Zoom by PBSS-SF Bay

Free Online Symposium: RNAi Therapeutics: Discovery, Preclinical and Clinical Development

Date/Time: Jan 19, 2021; 11:00 - 13:30 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration: https://www.pbss.org/aspx/homeSF.aspx




Online via Zoom by PBSS-SF Bay

Chinese American Biopharmaceutical Society (CABS) is proud to present 2021 Investor Forum at 4-7:30 pm PST on January 13, 2021, in conjunction with the JP Morgan Healthcare Conference. 

The Investor Forum will be joined by 16 China- and US-based investors, business development executives, and entrepreneurs. The topics will focus on the trends, opportunities and challenges in capital investment, business development and M&A, next generation of innovative therapeutics. The impact of COVID-19 and US-China relationship on Biopharma investment will also be discussed. The Investor Forum will be from 4 pm to 7:40pm.

  • 3 Panel Discussions; 16 High-Profile Guest Panelists
  • Next Wave of Innovative Therapies
  • Trends of Capital Raising in Biotech and Pharma
  • Building Cross-border Life Science Companies
  • Join at 4PM: Networking and Socializing over Zoom
  • Stay Until the End: Meet with Panelists over Zoom


Free Registration https://zoom.us/meeting/register/tJwkd-qvrD4vGtMjSvn8jgY6Pomwme58UnND

Please Update to to Latest Version of Zoom (click here to update) before Join-in. Otherwise You Cannot Use Zoom Breakout Room Function.


Agenda (Based on US Pacific Time)

4-4:50 pm: Networking in Zoom Breakrooms

4:55-5:00 pm: Opening remarks by Yang Tian, CABS President

5-5:50 pm Investor Forum Panel 1: Invest in Next Generation of Innovative Therapeutics

Moderator: Janet Xiao, Partner, Morrison & Foerster LLP

Panelists: Jennifer Goldstein, Managing Partner, Silicon Valley Bank

Nick Naclerio, Founding Partner, Illumina Ventures

Vincent Xiang, Founder and Managing Partner, 7G Bioventure

Michael Salgaller, Supervisory Specialist, Invention Development and Marketing, NIH

Howard Edelman, CEO, SeeMedX

5:50-6:30 pm Investor Forum Panel 2: Trends of Capital Raising in Biotech and Pharma

Moderator: Alex Zhang, CEO, Hanhai Silicon Valley

Panelists: Cherry Lu, Founding and Managing Partner, RedHill Capital

Thomas Chou, Partner, Morrison & Foerster LLP

Michael Chan, Head of International Issuer Services, Hong Kong Stock Exchange

Helen Chen, Greater China Managing Partner, Head of China Life Sciences, L.E.K. Consulting

6:30-7:10 pm Investor Forum Panel 3: Building Cross-border Life Sciences Companies: Challenges and Opportunities

Moderator: Cheni Kwok, Managing Partner and Founder, Linear Dreams

Panelists: Cynthia Cai, Venture Partner, Viva BioInnovator

Bin Li, Founder and CEO, Lake Bleu Capital

Hai Mi, Managing Partner, Panacea Venture

Scott Liu, Co-founder and Head of Strategic Advisory Committee, Henlius Biotech

7:10-7:40pm Meet with Panelists on Zoom

7:40pm End of event


Free Registration https://zoom.us/meeting/register/tJwkd-qvrD4vGtMjSvn8jgY6Pomwme58UnND


Investor Forum Panelists


Janet Xiao, PhD, JD, Co-Chair of Global Life Sciences Group, Morrison & Foerster LLP

Janet focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. She advises her clients on patent matters relating to various technologies, including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. Recognized by Chambers as being highly sought after for patent prosecution and strategy mandates by innovators from around the world, Janet develops and strengthens her clients’ complex patent portfolios to maximize their commercial value. She is instrumental in developing strategies for multibillion-dollar patent portfolios for pharmaceutical clients. Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products. She helps some of the world’s most-sophisticated biopharmaceutical companies and investors assess potential risks and devise preemptive risk-management strategies for their product development and investments. She has led hundreds of IP due diligence projects, and is noted for her in-depth knowledge of patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. Janet works regularly with patent litigators in the event of legal challenges by third-party competitors or vice versa, and she is frequently called upon to represent clients in litigation and post-grant proceedings. She is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. Since 2005, Janet has been actively involved in the leadership team of the Chinese-American Biopharmaceutical Society (CABS), a nonprofit organization dedicated to bridging the life sciences communities in the U.S. and China, including serving as president for the 2011–2012 term.  

Jennifer Goldstein, Partner, Silicon Valley Bank

Jennifer Goldstein is the Managing Partner for Life Science & Healthcare at SVB Capital and a founding member of Venture Forward, a non-profit that provides resources and education towards developing a diverse, equitable, and inclusive venture ecosystem. She is also an advisory board member of Springboard Enterprises and the Women’s Health Innovation Coalition. A bioengineer by training, Jennifer is passionate about the role that venture investing can bring to discovery in the fields of health care and life sciences. She is currently leading SVB Capital’s Life Science & Healthcare investment team and helping develop the bank’s first life science direct investment fund for institutional Limited Partners. Jennifer has more than 20 years of experience in the venture and startup market segments, including leading and building several teams over the past 8 years at Silicon Valley Bank. Prior to that, she was a director on Pfizer's Venture Capital team, where she helped lead or co-lead investments into several life sciences companies, led fund-of-fund investment decisions, and independently managed Pfizer’s $250 million private equity portfolio. Jennifer has also served as a consultant on private equity deals across Europe while at Bain & Company and has held operational and research roles at Chiron, Genelabs, and Genencor. Jennifer graduated magna cum laude with a BSE in Bioengineering and a Master's of Biotechnology from the University of Pennsylvania. She holds an MBA from the Wharton School, where she was named a Joseph Wharton Fellow. She also serves as an independent director at Alexandria Real Estate Equities, Inc.

Nick Naclerio, PhD, Founding Partner, Illumina Ventures

Nick is the Founding Partner of Illumina Ventures. His passion is building companies at the intersection of technology and human health. Prior to joining the fund, he served as SVP, Corporate & Venture Development for Illumina where he was responsible for strategic planning, business development, licensing, venture investing and acquisitions. In six years, Nick and his team completed ten acquisitions, more than a dozen venture investments, and a multitude of other transactions including the formation of Helix and GRAIL and the creation of a global NIPT patent pool. Nick also served as the founding General Manager of Illumina’s Enterprise Informatics Business Unit. Before joining Illumina, Nick co-founded and was the Executive Chairman of the diagnostics company Quanterix. Previously he was Executive Chairman of True Materials and CEO of ParAllele BioScience, life science tools firms that were both acquired by Affymetrix. Nick got his start in venture investing at Motorola where he led the life science investment team and served on the boards of the SNP Consortium, Genometrix, Clinical Microsensors, and Orchid Bioscience. He founded and led Motorola Life Sciences, an early microarray company that was acquired by GE. Previously he held leadership positions at DARPA and served on the board of SEMATCH. Nick is chairman of Serimmune and Stilla Technologies, and also serves on the boards of Baebies, Cradle Genomics, DNA Script, Genome Medical, LetsGetChecked and Pattern Bioscience. Nick received a B.S. in Engineering from Duke University, was a Winston Churchill Scholar at Cambridge University, and earned a Ph.D. in Electrical Engineering from the University of Maryland.

Vincent Xiang, PhD, Founding and Managing Partner, 7G BioVentures

Dr. Xiang has worked in the life sciences industry for more than 20 years, with rich experience in scientific research, product development, company management, investment and mergers and acquisitions. He led the $550M acquisition of US Epic Pharma, the largest M&A ever done by a Chinese healthcare firm in 2016. Dr. Xiang has comprehensive practical experiences in leading and managing top fund investment and financing business for many years, and has a deep understanding of the capital market. The pursuit of excellence in clinical data and his extensive industry network make him a well-known investment expert in the field of international pharmaceutical investment and financing. From 2018 to 2020, Dr. Xiang was Head of BioVenture at Hillhouse Capital with responsibilities of global venture capital investment, team building, procedures determination, decision making for investment projects. He personally led 9 investment projects ranging from series A round to crossover round while his team invested 31 projects successfully. From 2016 to 2018, Dr. Xiang was the partner at 6 Dimensions Capital, which is a leading healthcare focused investment firm with an in- depth focus and extensive coverage across China and the United States.  He led 8 projects and those 8 projects had been successfully set up in next round or already went IPO. He was awarded the best performance partner in investing achievements in 6 Dimensions. Prior to 2016, he worked as Managing Director and Head of international investments & business development at Humanwell Healthcare Group, Managing Director of Burrill Life Science Venture Capital Fund, Portfolio Manager/Analyst at Franklin Templeton. Dr. Xiang began his career at Sinopharm in China. Dr. Xiang received his Ph.D. in molecular biology from University at Stony Brook, MBA from the Wharton School, and B.S. in Immunology and Microbiology from Fudan University. He is a founding member of BayHelix Group, founders and board members of two life science startups.

Michael Salgaller, PhD, Supervisory Specialist of Invention Development and Marketing Unit, National Cancer Institute Technology Transfer Center

Dr. Michael Salgaller leads the Invention Development and Marketing Unit (IDMU) within the National Cancer Institute’s Technology Transfer Center, where he leverages over 20 years of business, scientific, and investment experience in various life science sectors to support licensing and technology development partnerships. The IDMU serves in a business development role to foster licensing and collaborative activity between buy-side stakeholders and the NIH. He is a long-time industry executive who held various positions in boutique professional service and early-stage biotechnology firms – as well as several years in government affairs and on the investment team of a venture capital firm dedicated to the life sciences. He is the author of “Biotechnology Entrepreneurship,” and teaches an entrepreneurship class at NIH. He is on the Board of Canines-N-Kids, a foundation supporting cooperation between researchers in pediatric and veterinary oncology. He has written over 100 articles, presentations, and book chapters. Dr. Salgaller received his PhD in Pathology from The Ohio State University.

Howard Edelman, Chairman of the Medical Device and Digital Health Screening Committee, Life Science Angels, CEO of SeedMedX

Howard Edelman is a medical device executive accomplished in all phases of medical product development and operations in a variety of organizational structures. Most recently, Mr. Edelman was General Manager of Cothera, a division of United Orthopedic Group, a global orthopedic company which provides medical devices and patient services into the secondary orthopedic market. Cothera was recently purchased by Breg in November of 2014. Previously, Howard Edelman was the Founder and CEO of VitalWear, a leader in thermal therapy. In 2009, VitalWear was named on the INC 500 list of fastest growing private companies and on the San Francisco Business Times Fast 100. In 2010, Medical Device & Diagnostic Industry listed VitalWear as one of the top 50 medical device companies to watch. Mr. Edelman has served in management roles in firms such as Johnson & Johnson, Zeiss, CooperVision, and Bio-Rad Laboratories and various startup companies in the Bay Area. Mr. Edelman is a member of the BayBio Expert Network and sat on the Research Committee for the Juvenile Diabetes Research Foundation. Mr. Edelman holds a B.S. in Biomedical Engineering from Boston University.

Alex Zhang, PhD, MBA, CEO of Hanhai Silicon Valley

Alex Zhang is the CEO of Hanhai Silicon Valley., an early stage investor and cross-border accelerator for startups in San Francisco Bay Area. Prior to Hanhai, Alex was the Managing Partner of Enverest, LLC., a Silicon Valley-based innovation solutions and investment advisory firm with branch offices in China and Singapore. Prior to co-founding Enverest, Dr. Zhang spent nearly five years at Thermo Fisher Scientific, where he was responsible for 4 business development deals exceeding $10 M, and played a key role in several billion-dollar acquisitions in MedTech. From 2001 to 2009, Dr. Zhang was a Senior Scientist at Tularik Inc. (acquired by Amgen in 2004), where he led drug discovery endeavors in oncology, cardiovascular and metabolic diseases therapeutic areas. Dr. Zhang received MBA degree at Cornell University, PhD in Organic and Analytical Chemistry at Texas A&M University, and BS in Chemistry at Shandong University. During his graduate research, he focused on the design and synthesis of therapeutic peptoids, as well as biological mass spectrometry. His research has led to publication of more than 20 peer reviewed articles and 4 patents. Dr. Zhang has served multiple leadership roles in the Executive Council of CABS, including as the President in 2017-18. Over the past decade, Dr. Zhang has advised a number of successful MedTech and digital health startups based in Silicon Valley.        

Cherry Lu, Funding and Managing Partner, RedHill Capital

Experienced Partner with a demonstrated history of working in the leading venture capital and healthcare industry. Strong business development professional graduated from The Chinese University of Hong Kong and Tongji Medical Academy of Huazhong Science & Technology University. The details are as follow:– 13 years at Sequoia Capital China, from analyst to partner in Sequoia’s history – Led investment in 30+ MedTech/Biotech companies and many of them has become sub-segment leaders, e.g. Jafron (300529, a leading enterprise in China blood purification industry), Snibe (300832, IVD), Winner Medical (300888), Iray(688301), Armo (ARMO, Nasdaq), XtalpI(Industry pacesetter), etc. – Industry recognition: Forbes 2020 Top 25 Female Venture Capitalists in China; Forbes 2018 Top 25 Female Venture Capitalists in China; Instructor for Merck China Innovation Center; FMBA instructor at Cheung Kong Graduate School of Business

Thomas Chou, Partner, Morrison & Foerster

Thomas Chou is a co-head of the firm’s Asia private equity practice and a leader in the firm’s China M&A practice, both of which are consistently highly ranked in major independent industry league tables and lawyer ranking organizations. Thomas’ corporate practice spans over two decades of experience in the U.S. and Asia Pacific region, focusing on cross-border mergers and acquisitions (inbound and outbound), joint ventures, as well as private equity and venture capital financings. His clients include industry leading growth companies as well the investors who fund them (private equity and venture capital funds, family offices, corporate/strategic investment arms of MNCs, insurance companies, and sovereign wealth funds). His practice is focused on the healthcare and life sciences, technology, media and telecom, and consumer and retail industries. He is ranked as a leading individual in China for Corporate/M&A and Private Equity: Buyouts & Venture Capital Investment  by Chambers Asia-Pacific 2020. He is also a leading individual for Private Equity and is highly recommended for Healthcare and Life Sciences by Legal 500 Asia-Pacific 2020. His clients pinpoint his “decades of venture capital experience both in the United States and in Asia,” with one noting: “He is patient, attentive to details and someone who has clearly conquered many battlefields.”

Michael Chan, Head of International Issuer Services, HKEX

Mr. Michael Chan, Head of International Issuer Services, leads the international IPO and issuer marketing efforts for HKEX. Mr. Chan is mainly focused on market development work promoting the Hong Kong listing platform and origination work attracting international and biotechnology companies to list in Hong Kong. In addition to leading the marketing efforts globally and working closely with prospects and constituents, Mr. Chan often speaks and serves as panelist and keynote speaker at major conferences and events locally and internationally. Prior to his current role, Mr. Chan has worked at the Listing Division of HKEX for 8 years covering areas of compliance, corporate governance, regulatory and IPO-related matters. Prior to joining HKEX, Mr. Chanhas worked at various financial institutions in corporate finance and business development. Michael has more than 18 years of experience in financial services and regulatory work.

Helen ChenGreater China Managing Partner, Head of China Life Sciences, L.E.K. Consulting

Helen Chen is the Greater China managing partner of L.E.K. Consulting based in Shanghai, and a winner of the prestigious Global Leaders in Consulting for 2019 award from Consulting Magazine.  She sat on L.E.K.’s Global Leadership Team, the firm’s governing board, from 2012 to 2016, and served as the head of L.E.K.’s China practice from 2011 to 2018 and Asia life sciences practice from 2015 to 2019. Helen has over 30 years of consulting and industry experience in the U.S. and Asia, and has resided in China since 2000. Helen is the head of L.E.K.’s China healthcare practice and a board member of L.E.K.’s Asia Pacific Life Sciences Centre of Excellence, supported by Singapore’s Economic Development Board.  She has extensive case work and industry experience covering the full biopharmaceutical and medtech value chain, ranging from early research services to post-market product positioning and sales force effectiveness.  In China, she has developed commercial strategies for international biopharmas and medtechs, investment thesis for financial investors, business plans for domestic startups and policy analyses for industry associations. Helen is a frequent speaker and author on the opportunities and issues in the China healthcare and life sciences, and has been quoted by publications including BioCentury, BioWorld, In Vivo, Wall Street Journal, South China Morning Post, Financial Times and Forbes AsiaPrior to joining L.E.K., Helen was an associate director of finance at Genentech (now Roche) and a sales planner at Abbott Laboratories (now AbbVie).  She was on the Board of Pharmaceutical Management Sciences Association from 1995 to 1997. Helenreceived her A.B. cum laude in applied mathematics from Harvard University.

Cheni Kwok PhD, CLP, Managing Partner and Founder, Linear Dreams

Dr. Kwok is a senior biopharmaceutical executive with broad operational expertise who has executed over 150 transactions including M&A, strategic partnerships, licensing, divestitures, spin-offs and project financing. Dr. Kwok is the Managing Partner and Founder of Linear Dreams LLC, a management consultancy for the life sciences industry. The firm’s engagements include a broad range of business and corporate development activities including managing business development teams, product and technology licensing, search & evaluation of products and technology platforms, merger & acquisitions, corporate strategy, portfolio planning, market and competitive intelligence, due diligence support for financing as well as valuation services for 45 biopharmaceuticals companies, contract research & non-profit organizations, research institutes and investors in USA, Europe, China, Taiwan and Singapore. As Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., Dr. Kwok established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, she was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics, including the divestiture of the oncology pipeline (including Imbruvica® (ibrutinib)) to Pharmacyclics Inc. (now an AbbVie Company). Dr. Kwok held business development positions of increasing responsibility at Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., she held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK). Dr. Kwok received a bachelor's degree with first class honors in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, a Ph.D. in human molecular genetics from the University of Cambridge, UK and has earned the Certified Licensing Professional (CLP) credential. At present, Dr. Kwok is serving as the Board of Directors of Chinese-American Biopharmaceutical Society (CABS) and serves on the Standards, Admissions & Recertification committee of Certified Licensing Professionals, Inc..

Bin Li, PhD, Founder and CEO, Lake Bleu Capital

Dr. Bin Li is the founder and CIO of Lake Bleu Capital, an Asian healthcare investment firm based in Hong Kong and Shanghai. Previously, he was a Partner at Ally Bridge Group and prior to that he was a Managing Director and the Head of Greater China Healthcare Research at Morgan Stanley. Since he moved to Morgan Stanley and established the healthcare research practice in Hong Kong in 2008, he had been ranked as the top analyst in China healthcare industry by the most widely recognized investor surveys, including: No. 1 Asia Healthcare Analyst by the Institutional Investor (II) for seven consecutive years (2008-2014); No.1 China Healthcare Analyst each year by II since the poll started in 2010 (2010- 2014); No. 1 in Wall Street Journal's “Best Asia Healthcare Analysts” in 2010 for his stock selectionNo. 1 Asia Healthcare Analyst by other independent investor surveys including Greenwich and AsiamoneyBefore joining Morgan Stanley, he was a senior healthcare research analyst at Merrill Lynch (Hong Kong) and responsible for the firm’s stock research efforts on Asia healthcare. Before moving to Hong Kong in 2007, he was a key member of a top-rank US pharmaceutical research team at Merrill Lynch based in New York. Dr. Li has over 20-year experience in healthcare industry. He received his Ph.D. in biochemistry and MBA from New York University and bachelor’s degree in chemistry from Fudan University, China. Prior to his sell-side career, he worked at Merck Research Laboratory as a scientist and published papers on peer-reviewed science journals.

Cynthia Cai, PhD, MBA, M. Eng, President, Tharton Consulting; Venture Partner, Viva BioInnovator; Senior Advisor, Northern Light Venture Capital 

Dr. Cynthia Cai is an executive and investor with over twenty-five years of experience in healthcare and life science industry. International experience in sales, marketing, business development, and equity investment.  In-depth understanding of global biotech and life science business, widely recognized as having a unique ability to bridge collaborations between technology and business, between the west and east culture. Currently, Dr. Cai is an investor targeting early-stage opportunities of innovation and disruptive technology in healthcare field. Prior to that, Dr. Cai had over 20 years of experience in leadership positions with one of the world’s most respected life science companies. As senior director of marketing in Agilent Technologies, she was responsible for its billion-dollar Chromatography, automation and Mass Spec. business. As business development manager and product marketing manager, Dr. Cai was involved in multiple acquisitions and divestitures, also led a $500+ million-dollar flagship product development and its global commercialization. Dr. Cai earned a B.A. and Master of Engineering from Tsinghua University, received her Ph.D. in Chemistry from the University of Massachusetts, and MBA from The Wharton Business School of the University of Pennsylvania. She served as Delaware governor economic advisor, a member of the Board of the Forum for Executive Women (FEW-DE). She has also been a mentor for Wharton EMBA, Tsinghua University Global MBA and Drexel LeBow School of Business for many years. Dr. Cai had been a regular speaker at healthcare conferences such as BIO; RESI; China Focus at J.P. Morgan, SAPA Annual Conference and Wharton China Business Forum.

Hai Mi, PhD, Managing Partner, Panacea Venture

Dr. Hai Mi is a Founding and Managing Partner of Panacea Venture. Prior to Panacea Venture, a life science VC focuses on early-stage investment and incubation, Hai joined Kleiner Perkins Caufield & Byers China as a Partner in 2015 and focuses on the firm’s life sciences practice. Prior to joining KPCB China, Hai was a partner at DT Capital responsible for investment in life science, healthcare and other related fields. Hai was a venture partner of SB China Venture Capital (SBCVC) and his investment transactions include BGI, SyMap Medical and Precise Light.  Hai was Senior Director of Strategic Planning and then Vice President of Corporate Communications at WuXi Pharma Tech (NYSE: WX) in Shanghai where he played an important role in NYSE listing, and the acquisition of AppTec in US.  He also served on the board of Chemspec International (NYSE: CPC) as an independent board director and the chairman of audit committee, and he participated in the privatization of Chemspec.  Earlier Hai was a research scientist at Pfizer in the US. Hai obtained a PhD in Organic Chemistry from New York University, an MBA from The University of Chicago Booth School of Business, and a B.S. in Material Science from Fudan University in Shanghai.

Scott Liu, PhD, Co-founder and Head of Strategic Advisory Committee, Henlius Biotech

Dr. Scott Liu, the co-founder and Head of Strategic Advisory Committee at Shanghai Henlius Biotech Inc., a global biopharmaceutical company focusing on the development, production and commercialization of high-quality and affordable biosimilar, biobetter and novel therapeutic monoclonal antibodies. Dr. Liu has more than 25 years of experience in biopharmaceutical R&D, manufacturing and quality management. Prior to setting up Henlius in 2010, he has previously had postdoctoral training in Biology at Stanford University and has served several executive positions at United Biomedical, the Founding Director of the Biologics QC Department at Bristol-Myers Squibb Technical Operations, and the Director of QAL (QC) at Amgen Inc. Fremont (now Boehringer Ingelheim Fremont Inc.). Dr. Liu was the recipient of the Bristol-Myers Squibb “Technical Operations Presidential Award” in 2004. Furthermore, Dr. Liu led the promotion of industry-wide adoption of single-use manufacturing technology to support the production of clinical and commercial monoclonal antibody therapeutics, and actively participated in the development of Technical Guidelines of Biosimilar Development and Evaluation to promote the innovation and globalization of the biopharmaceutical industry in China. He received his Ph.D. degree in Biology from the Purdue University.


Free Registration https://zoom.us/meeting/register/tJwkd-qvrD4vGtMjSvn8jgY6Pomwme58UnND

Please Update to to Latest Version of Zoom (click here to update) before Join-in. Otherwise You Cannot Use Zoom Breakout Room Function.



Online Zoom conference (register on Zoom below)

Conference Name: 2021 CTIC 5 th Pre-JPM Healthcare Investment Summit

Date: January 9-10, 2021

Format: Virtual Conference

Conference Website: ctic-conferences.com


Host: CTIC Capital

Co-host: Bayhelix

Supporting Organizations: CABS, BioCentury, CLSI, CLSA


CTIC summit stands out as it was the only large conference during JPM where there were more investor attendees than company executives.  We are also the only cross-border event with sponsorships coming from Asian venture investors for the past four years (check our previous summits).   

2021 summit will feature live and on-demand presentations and discussions from CEOs, investors, and leaders in healthcare sectors:

Partnering Program:  Investors to company executives ratio of 1:1 

Investor Showcases: Featuring the US and Asian investors with their latest investment focus, personal stories, and insights

Company Showcases: Featuring selected global healthcare companies with cutting edge technologies (15 minutes presentation + 10 minutes on-screen discussion with a paired investor) Application submission deadline is December 26, 2020 

Virtual Exhibition: Unlimited possibilities with the digital and interactive exhibition opportunity

Fireside Chats and Panel Discussion Topics: Latest updates and strategies for cross-border fundraising, business development, and collaborations

Virtual Networking Sessions

CABS member special invitation code: CABS2021 (20% off)

Registration Link: https://www.eventbrite.com/e/ctic-5th-pre-jpm-healthcare-investment-summit-tickets-128559391601


Scan the code to register


For more details about 2021 CTIC Healthcare Investment Summit, please visit ctic-conferences.com.



Virtual Conference

Free Online Symposium: Readying for the Vaccines: Latest Updates on COVID-19 Vaccine Development and Implementation

Date/Time: Dec 21, 2020; 11:00 - 13:30 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details & Registration: https://www.pbss.org/aspx/homeSF.aspx



Online via Zoom by PBSS-SF Bay

Free Online Symposium - Day 2: Preclinical Models to Guide Therapeutic Development in Oncology

Date/Time: Dec 15, 2020; 8:45 - 13:00 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details& Registration: https://www.pbss.org/aspx/homeSF.aspx




Online via Zoom by PBSS-SF Bay

CABS Entrepreneurship Club Workshop

“Entrepreneurship and Investment“

Date:December 12, Saturday, 1:00-3:00 PM.

Location: https://zoom.us/j/99662926044

Zoom ID: 996 6292 6044


Speakers Bio:

Huijun Zhou, Ph.D., CABS Enterpreneurship Club Program Chair

Dr. Huijun Zhou is CEO and co-founder of Doctor Chain LTD and iDNA Inc. Dr. Zhou received her Ph.D. in molecular biology and genetics from Cornell University and completed her post-doctoral medical genetics training at the Stanford University School of Medicine. She is a clinical molecular geneticist, board-certified by the American Board of Medical Genetics. She currently serves as the Program Chair of Chinese American BioPharmaceutical Society (CABS) Entrepreneurship Club.


Hong I. Wan, Ph.D. is president, chief executive officer and director of Tallac Therapeutics. Previously as chief scientific officer and a member of the founding management at ALX Oncology, she led the team to advance ALX148, a best-in-class myeloid checkpoint inhibitor, for multiple tumor indications. Prior to ALX Oncology, Dr. Wan held various leadership positions at Pfizer and Wyeth Research, where she was responsible for the early development and translational medicine strategy and execution across various therapeutic areas. Dr. Wan started her career at Renovis where she led discovery programs in neuroinflammation. Dr. Wan received her Ph.D. in molecular and cell biology from University of California, Berkeley and A.B. degree in biochemical sciences from Harvard University.


Keting Chu is a scientist, entrepreneur and life science venture investor with a broad range of experiences in therapeutic development and venture investment.keting is Executive Chairman of the board at Bluejay Therapeutics currently. Keting was previously a partner and venture Partner of Lyfe Capital that is focused on healthcare VC investments in the US and China. Prior to joining Lyfe Capital, Dr. Chu was venture partner at Apple Tree Partners. Before joining Apple Tree Partners, Keting spent fiveyears as VP, Research TAP at The Leukemia and Lymphoma Society (LLS), and is responsible for venture philanthropy. Prior to LLS, Keting co-founded, as head of RnD or CEO, four biotech companies including Five Prime Therapeutics, Bio3, DigitAB and Mission therapeutics. Before that, Keting was the Head of Immunotherapy and Antibody Therapeutics Division at Chiron Corporation and she was responsible for the R&D pipeline of biologic. Keting received her MD in Sun Yat-sen Medical University specialized in infectious diseases in China, Ph.D. in Microbiology and Immunology at University of California at San Francisco (UCSF).


Lue Sun is now the Vice President of 3E Bioventures, a venture capital focus on healthcare investment. Prior to 3E, Lue worked at Fusion Fund in Palo Alto and led several investments, including Proscia, Loop Genomics, Quantapore, Huma.ai, and Subtle Medical. He received a Ph.D. in Biology from Tsinghua University before joined Fusion. By focusing on cross-sector innovation, Lue has invested and become the board member of Chigene and Subtle Medical since joining 3E. Meanwhile, he also covers deals in AI applications, Med Tech, Diagnostics, and Liver Diseases.

Please Mark Your Calendar

Annual CABS Entrepreneurship Club Innovation Roadshow | January 13, 2021 | Zoom

CALL FOR PROPOSALS




Online Webinar through Zoom Conference

Free Online Symposium: Engineering NK Cells for Immunotherapy

Date/Time: Dec 10, 2020; 12:00 - 13:30 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details& Registration: https://www.pbss.org/aspx/homeSF.aspx




Online via Zoom by PBSS-SF Bay

Free Online Symposium - Day 1: Preclinical Models to Guide Therapeutic Development in Oncology

Date/Time: Dec 8, 2020; 8:45 - 13:00 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details& Registration: https://www.pbss.org/aspx/homeSF.aspx




Online via Zoom by PBSS-SF Bay

Time: December 7, 2020 (Monday) - 8pm ET, 5pm PST, US time

Registration: https://zoom.us/meeting/register/tJwvf--rqjsjEtFPbmlB0m3SvXCu59f9BHqS

Join us for the presentation, "From Foundations to Frontiers", a landmark study of the enduring contributions of Chinese Americans to American society from the 1800s to today.

The evidence-driven study details the contribution across the following seven industries: Arts&Culture, Civil Rights, Public Service and Politics, Business Leadership & Entrepreneurship, Infrastructure, Military & National Security, Public Health, and Science & Technology.

From Chih-Tang Sah and the semiconductor revolution to Chien-Shiung Wu and the Manhattan Project, Chinese Americans have played an integral, but often overlooked part in the technological growth of the United States.

Presented by Committee of 100 President Zhengyu Huang, this virtual presentation will provoke curiosity and offer a new perspective on Chinese American contributions, while identifying, quantifying and showcasing the contributions of the Chinese American community through data and storytelling.

The event will be a 30 minute presentation followed by a facilitated discussion.

Time: December 7, 2020 (Monday) - 8pm ET, 5pm PST, US time

Registration: https://zoom.us/meeting/register/tJwvf--rqjsjEtFPbmlB0m3SvXCu59f9BHqS

Speaker

Zhengyu Huang, President,  Committee of 100

Zheng was born in Shanghai, China and came to the US at the age of ten. Zheng was educated at Stanford University, with a B.S. in Industrial Engineering, B.A. in Economics, and M.S. in Computer Science. He also earned his MBA from Harvard Business School. After graduation, Zheng worked at Intel Corporation and rose to Managing Director and then served under President Obama as a White House Fellow and special assistant to the Administrator for US Agency for International Aid. Thereafter, he started a financial service data firm that grew to 300 staff and 7 offices. He was most recently the Chairman of an education focused investment firm. He is the author of three books published in China that sold over 250,000 copies. He has lived in five countries, including the US, Germany, Japan, India, and China and traveled to over 80 countries.


Zoom



Free Registration at:https://zoom.us/webinar/register/WN_j4VcFTRTTSat9j-yCGYEZw

Speakers Bio


Janet Xiao, PhD

Patent Partner, Morrison & Foester LLP

Dr. Janet Xiao, patent partner at Morrison & Foerster LLP and head of firm’s China Life Sciences Group, focuses her practice on worldwide patent procurement, patent portfolio management, and strategic planning for life sciences companies. Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, and marketing and manufacturing clearance for biopharmaceutical products. Full bio


Yan Qi, PhD

Patent Associate, Morrison & Foerster LLP

Dr. Yan Qi, patent associate at Morrison & Foerster LLP, is committed to delivering targeted solutions to clients’ diverse intellectual property needs in the life sciences. Her practice includes patent preparation and prosecution, freedom-to-operate, landscape and patentability analyses, intellectual property due diligence, and patent litigation support. Yan applies her bilingual language skills to assisting crossborder matters involving Chinese companies. Full bio


Yuying (Kate) You, PhD

Patent Associate, Morrison & Foester LLP

Dr. Yuying (Kate) You, patent associate at Morrison & Foerster LLP, focuses her practice on patent preparation and prosecution, strategic portfolio management and IP due diligence. She helps emerging and established companies build strong patent portfolios in diverse technologies including biologics (such as antibody therapy), cell therapy, immuneoncology therapy, gene therapy, drug delivery systems and diagnostics. Full bio

If you have any particular question that you wish the speakers to discuss during the workshop, please feel free to send an email to Yuying (Kate) You via yyou@mofo.com.


Online Webinar through Zoom Conference


Free Online Symposium: The Drug Discovery and Development Journey of Polivy (Polatuzumab Vedotin): An Antibody- Drug Conjugate for the Treatment of Diffuse Large B-Cell Lymphoma 

Date/Time: Nov 13, 2020; 11:00 - 13:00 (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details& Registration: https://www.pbss.org/aspx/homeSF.aspx




Online via Zoom by PBSS-SF Bay
Title - Getting Back to Normal: Tools and Practices.
When - 31st October'2020 at 3:00pm - 4:30pm PDT

Register here https://bit.ly/31lnJB8








Online

Free Online Symposium: No More Undruggables: Unconventional Approaches for Drug Discovery and Design - Prodrugs, PROTACS, Fragment-based Design, Directed Evolution and Beyond

Date/Time: Oct 29, 2020; 4:00 PM - 7:00 PM & Oct 30, 2020; 9:00 AM -12:00 PM (PST) 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details& Registration: https://www.pbss.org/aspx/homeSF.aspx




Online via Zoom by PBSS-SF Bay


We invite your participation to this exciting event by EPPIC Global, sponsored by Jubilant Biosys Limited on the role of AI/ML in drug discovery.

Machine learning, artificial intelligence, deep learning are buzz words we've all heard, as these technologies promise to transform the landscape of drug discovery. Hear about decoding biology through target-agnostic and engineering mindset approach. Learn about the power of linking different computational technologies needed for Lead Optimization such as multi-parameter optimization platform and experimental integration. Understand insights on pre-competitive consortia and public-private partnerships, different AI/ML approaches taken and expected output.  

But how exactly do they work? What are the tools and various approaches? How AI is addressing the various challenges of the drug discovery process? What are the limitations of each approach? What it can/cannot do? What are the requirements for their successful implementation?

This session will be moderated by Anjali Pandey and will have presentations by Sharath Hegde, Stacie Calad-Thomson, Andrew Radin and Tarangini (Gini) Deshpande.

Title: Role of AI/ML in transforming and accelerating the drug discovery process
Timing: 17 October 2020, 3:00 PM- 4:30 PM, PDT
Register here for $10 - https://bit.ly/30EeD22


Online
Dear guests of BioPacific Toastmasters Club,

We at the BioPacific Toastmasters club would like to invite you to join our first-ever virtual open house!

The theme of this special edition of open house is "Take Me Home, Country Roads". Everyone is encouraged to set your Zoom virtual background to something related to your hometown OR some objects you have that are related to your hometown, and everyone will have a chance to talk about it in the table topics session.

The open house will be held on Saturday, September 26th, from 6:00 to 7:15 PM. It will feature a prepared speech, an extended table topics session, and social time for the guests and members to get to know about each other as well as the club. The Zoom meeting link will be provided to the registered guests.

Please check out the attached flyer for more information. The registration link is https://forms.gle/bz1kUzAfv6ncB1xG9, which is also available in the flyer as a QR code.

New to Toastmasters? Check out https://www.toastmasters.org/membership/why-toastmasters for a great introduction.

Interested in our club? Visit https://biopacific.toastmastersclubs.org/




Zoom Conference


CABS Webinar

Leverage Global Clinical Resources for Drug Development

US Pacific Time: September 25 (Friday), 2020, 2:00pm-4:00pm


How to Perform Early Stage Trials in US

China Drug Regulatory Reform and Include China in Next Trial

Manage Global Clinical Trials During COVID-19 Pandemic

Webinar is Free and No Registration Required

Join Webinar through Zoom:

https://zoom.us/j/97109756764

Add to Outlook Calendar

Add to Google Calendar

(Wechat user, please click upper right corner and choose "open in Safari", then you can add to calendar with one click)

Agenda

(This event will be broadcast to you through Zoom Conference; agenda is based on US Pacific Time)

2:00pm - 2:05pm Introduction to CABS, Dr. Yang Tian, President of CABS

2:05pm - 2:40pm Phase I Clinical Trials in the USA – Maximizing Value, Managing Risk. Lisa E. Diamond, PhD, President, Frontage Clinical Services.

2:40pm - 3:15pm Including China into Your Drug Development Strategy: Why, When, and How. Jiansong Yang, PhD, CSO and SVP, Tigermed

3:15pm - 3:50pm China’s significant role in the handling of COVID-19 global pandemic. Melika Davis, MS, VP, and Le Dao, BS, PMP, Associate Director, BeiGene

3:50pm - 4:10pm Panel Discussion


Speaker


Lisa E. Diamond, PhD, President, Frontage Clinical Services

As President of Frontage Clinical Services since 2018, Dr. Diamond provides oversight for Clinical Study Conduct and Analyses, Client Relations, and Business Development activities.

Dr. Diamond joined Frontage as Director of Clinical Affairs in 2005, was Vice-President of Clinical Affairs and Project Management in 2009-2013, and rejoined Frontage in 2017 as Vice-President of Clinical Affairs, US and China. In these positions she managed cross-functional teams, including Data Management, Programming, Biostatistics, Project Management and Medical Writing, provided Clinical Operations oversight and supported Business Development and Client Relations. Her prior positions in academia, small biopharmaceutical companies, Palatin Technologies, DNX and Nextran (1989-2005) and at Bristol-Myers Squibb (2013-2017), contribute to a broad experience base in research and development, preclinical and clinical research, a detailed knowledge of GCP/ICH guidelines, and a solid background in oncology, immunology, diabetes, autoimmune disease and transplantation research.

Dr. Diamond earned her Doctor of Philosophy and Master of Science degrees in Basic Medical Sciences from New York University (New York, Ny), and her Bachelor of Science degree from Suffolk University (Boston, MA). She completed her post-doctoral training at Princeton University (Princeton, NJ), and is an adjunct professor at Rider University (Lawrenceville, NJ).



Jiansong Yang, PhD, CSO&SVP, Tigermed

Dr. Jiansong Yang is the Chief Scientific Officer of Tigermed, which is the largest clinical CRO in China. He’s also the Founder and CEO of Mosim (now a Tigermed company), where he leads a team of over 100 scientists focusing on drug development strategy, clinical study design and PK/PD data analysis.

Dr Yang has over 15 years of experience in the pharmaceutical industry, specialized in early drug development and clinical study design. Prior to Mosim, he was Director of Clinical Pharmacology at GSK. He received his Ph.D. on Clinical Pharmacokinetics from the University of Sheffield, UK.

Melika Davis, MS, Vice President,BeiGene

Melika is the VP of Global Clinical Operations at BeiGene and leads a team of about 400 associates around the world, responsible for the planning and execution of all Clinical Trials’ activities.

Melika has 15 years of senior management experience and 25 years of Clinical Research and Development Quality Assurance experience.  Through designing and building successful global organizations, Melika and her teams have brought, on the worldwide market, 20+ products in the last 10 years, mainly in Oncology, Vaccines, and Anti-Infectives. Melika has led teams up to 700+ associates in Clinical Monitoring Operations and managed a portfolio up to 1,500 clinical trials a year.

Prior to joining BeiGene, Melika held numerous positions at Novartis and Schering Plough Research Institute of increasing responsibilities across the Research and the Development organizations in the areas of Oncology, Transplant, Anti-Infective, Respiratory, and Vaccines.

Melika holds a Master’s degree in Molecular Biology from Texas Women’s University in Dallas, Texas and a License de Physiologie from the University of Sciences in Nice, France.


Le Dao, BS, PMP, Associate Director, BeiGene

Le is an Associate Director of Portfolio and Program Management at BeiGene and is responsible for management of clinical programs in early stage development. She has 20+ years of clinical development experience and PM expertise that includes team management, business insights, clinical pharmacology (PK/PD) and combination product development across multiple disease areas, including oncology/CIT, immunology, and infectious disease. She has a strong record of collaboration across multidisciplinary functions in building and delivering on strategic plans. In addition to her technical industry expertise, she is passionate about making a meaningful difference in patients’ lives, community building, and leadership development.

Le holds a Bachelor’s degree in Chemistry from University of California, Los Angeles.


Webinar is Free and No Registration Required

Join Webinar through Zoom:

https://zoom.us/j/97109756764

Add to Outlook Calendar

Add to Google Calendar

(Wechat user, please click upper right corner and choose "open in Safari", then you can add to calendar with one click)





Zoom Conference

Free Online Symposium: Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond

Date/Time: Sept 17 & 18, 2020; 8:30 - 12:00 

Venue: Online via Zoom by PBSS-SF Bay

Organization: PBSS (Pharmaceutical and BioScience Society) 

Details& Registration: https://www.pbss.org/aspx/homeSF.aspx



Online Webinar through Zoom Conference

Antibody Drug Conjugates Seminar

On August 29, 2020, the Chinese American Biopharmaceutical Society (CABS) successfully hosted a webinar on Antibody Drug Conjugates (ADCs).

With the accelerated approval of Trodelvy in 2020, nine antibody drug conjugates now on the market have truly proven their potential. During the webinar, five experts from Seattle Genetics, Sutro Biopharma, Genentech, and Eli Lilly delved into the pioneering development of ADC from its early discovery to manufacturing CMC and clinical study. The speakers also emphasized the recent application of the ADC in fields other than oncology.

The webinar attracted more than 200 attendees from the biotech and pharmaceutical communities.

 

Dr. Ken Zhang, Co-Chair of Science and Technology Committee of CABS, kicked off the webinar with an introduction of CABS and Science Committee’s previous events.